1-4 of 4
Grace-Julia Okoroji, MS
Close
Sort by
Journal Articles

Busulfan and Fludarabine Conditioning Regimen Negates the Impact of Comorbidity Score on Nonrelapse Mortality in Patients with AML/MDS

Uday Popat, MD, Rima Saliba, PhD, Leandro de Padua Silva, MD, Borje S Andersson, MD, PhD, Amin M Alousi, MD, Paolo Anderlini, MD, Marcos de Lima, MD, Grace-Julia Okoroji, MS, BS, Chitra M Hosing, MD, Roy B Jones, MD, PhD, Partow Kebriaei, MD, Issa Khouri, MD, Yago Nieto, MD, PhD, Muzaffar H Qazilbash, MD, Richard Champlin, MD, Sergio A Giralt, MD
Journal: Blood
Blood (2008) 112 (11): 799.
https://doi.org/10.1182/blood.V112.11.799.799
Published: 2008
Journal Articles

Efficacy and Safety of Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan in Autologous and Nonmyeloablative Stem Cell Transplantation (NST) for Relapsed Non-Hodgkin’s Lymphoma (NHL).

Issa F. Khouri, MD, Rima M. Saliba, PHD, Chitra Hosing, MD, Rosamar Valverde, RN, William D. Erwin, MS, Luis Fayad, MD, Farzaneh Maadani, BS, Martin J. Korbling, MD, Grace-Julia Okoroji, MS, Anne M. Stachowiak, BS, Barry I. Samuels, MD, Paolo Anderlini, MD, Daniel R. Couriel, MD, Marcos de Lima, MD, Sergio Giralt, MD, Uday Popat, MD, Partow Kebriaei, MD, Naoto T. Ueno, MD, Muzaffar H. Qazilbash, MD, Peter W. McLaughlin, MD, Fredrick B. Hagemeister, MD, Anas Younes, MD, Donald A. Podoloff, MD, Richard E. Champlin, MD
Journal: Blood
Blood (2006) 108 (11): 315.
https://doi.org/10.1182/blood.V108.11.315.315
Published: 2006
Journal Articles

The Influence of PET/Gallium (PET/Gal) Status and High-Dose Rituximab (HDR) in Patients with Aggressive, Large, B-Cell Lymphoma (LBCL) Receiving Autologous Stem Cell Transplants (ASCT).

Amin M. Alousi, MD, Rima M. Saliba, PhD, Grace-Julia Okoroji, MS, BS, Chitra Hosing, M.D., Barry I. Samuels, M.D., Richard E. Champlin, M.D., Issa F. Khouri, M.D.
Journal: Blood
Blood (2006) 108 (11): 3058.
https://doi.org/10.1182/blood.V108.11.3058.3058
Published: 2006
Journal Articles

Campath-IH Combined with Fludarabine/Cyclophophamide/Rituximab (FCR) as Conditioning for Unrelated Non-Myeloablative Hematopoietic Transplantation (NMT) for Non-Hodgkin’s Lymphoma (NHL): Low Mortality Rate and Lower Than Expected Incidence of Cytomegalovirus (CMV) Reactivation.

Issa F. Khouri, MD, Jeffrey J. Tarrand, MD, Grace-Julia Okoroji, MS, Rima M. Saliba, PhD, Chitra M. Hosing, MD, Daniel R. Couriel, MD, Partow Kebriaei, MD, Donna Griffith, RN, Gabriela Rondon, MD, Cindy Ippoliti, PharmD, Richard E. Champlin, MD
Journal: Blood
Blood (2005) 106 (11): 2902.
https://doi.org/10.1182/blood.V106.11.2902.2902
Published: 2005